Home › Lymphangioleiomyomatosis › NCT02432560

Safety and Durability of Sirolimus for Treatment of LAM

Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)

Who can join

Ages 18 and older · Women

Inclusion Criteria:

* Female or male, age 18 or over
* Diagnosis of LAM based on ATS/JRS criteria
* Signed and dated informed consent
* On chronic therapy, newly treated or may be considered for therapy with mTOR inhibitors or previously intolerant of or having failed mTOR inhibitor therapy

Exclusion Criteria:

* Inability to attend at least one RLD Clinic visit per year
* Inability to give informed consent
* Inability or unwillingness to perform pulmonary function testing

About the study

The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.

What is being tested

• Sirolimus (drug)
• Everolimus (drug)

Sponsor: University of Cincinnati · Participants: 600 · Started: 2015-03

Contact the study team

• Susan McMahan Sellers, BSN, RN · Phone: (513) 558-4376
• Francis X McCormack, MD · Phone: (513) 558-0588

Official record on ClinicalTrials.gov — NCT02432560

Locations in the U.S.

Conditions

• Lymphangioleiomyomatosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.